Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5C | P41229 | 8/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.41 |
| ▸ | KDM6B | O15054 | 5/20 | 0.41 |
| ▸ | KDM4A | O75164 | 3/20 | 0.41 |
| ▸ | KDM5A | P29375 | 2/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 5/20 | 0.38 |
| ▸ | KDM3A | Q9Y4C1 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16922676 | 0.81 | KDM4C (0.44) | KDM5CKDM4CKDM5BKDM6BKDM4A | |
| SCHEMBL18708386 | 0.78 | KDM5B (0.47) | KDM5CKDM4CKDM5BKDM6BKDM4A | |
| SCHEMBL15636442 | 0.77 | KDM5B (0.52) | KDM5CKDM4CKDM5BKDM6BKDM4A | |
| SCHEMBL16912745 | 0.74 | FPR2 (0.46) | KDM5CKDM4CKDM5BKDM4AKDM5A | |
| SCHEMBL15637391 | 0.73 | KDM4C (0.44) | KDM5CKDM4CKDM5BKDM6BKDM4A | |
| SCHEMBL17144250 | 0.72 | CYP2D6 (0.46) | KDM5CKDM4CKDM5BKDM6BKDM4A | |
| SCHEMBL16291664 | 0.72 | KDM4C (0.43) | KDM5CKDM4CKDM5BKDM6BKDM4A | |
| SCHEMBL17144249 | 0.71 | ALDH1A1 (0.39) | KDM5CKDM4CKDM6BKDM2BPROKR1 | |
| SCHEMBL16291490 | 0.71 | HRH3 (0.45) | KDM5CKDM4CKDM5BKDM6BKDM4A | |
| SCHEMBL19549147 | 0.71 | KDM4C (0.40) | KDM5CKDM4CKDM5BKDM6BKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10189787-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9611219-B2 | — | — | 2017-04-04 | — | — | US | disclosed |
| US-9611220-B2 | — | — | 2017-04-04 | — | — | US | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189787-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM4C 56/4885KDM5B 34/4885 |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM4C 56/4885KDM5B 34/4885 |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM4C 56/4885KDM5B 34/4885 |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM4C 56/4885KDM5B 34/4885 |
| US-10221139-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM4C 56/4885KDM5B 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.